Ajinomoto has been granted a patent for compositions containing specific ratios of amino acids, including leucine and phenylalanine, which have been found to improve cognitive function, reduce anxiety-like symptoms, and suppress cerebral atrophy. The compositions are safe for continuous ingestion or administration. GlobalData’s report on Ajinomoto gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Ajinomoto, cancer treatment biomarkers was a key innovation area identified from patents. Ajinomoto's grant share as of September 2023 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a composition to improve cognitive function
A recently granted patent (Publication Number: US11752134B2) describes a method for improving cognitive function, anxiety-like symptoms, and suppressing cerebral atrophy. The method involves administering a composition containing specific amino acids to a subject in need.
The patent claims that the composition for improving cognitive function, anxiety-like symptoms, and suppressing cerebral atrophy should contain the following amino acids in specific proportions relative to the total content of leucine, lysine, valine, isoleucine, phenylalanine, histidine, and tryptophan. The amino acid contents should be as follows: leucine (25 mol% to 45 mol%), phenylalanine (20 mol% to 40 mol%), lysine (10 mol% to 30 mol%), valine (2 mol% to 7 mol%), isoleucine (5 mol% to 15 mol%), histidine (2 mol% to 10 mol%), and tryptophan (0.1 mol% to 2 mol%).
The patent also mentions that the composition can be in the form of a pharmaceutical product or a food.
This patent provides a method for improving cognitive function, anxiety-like symptoms, and suppressing cerebral atrophy by administering a specific composition containing amino acids in defined proportions. The amino acids mentioned in the patent have been associated with various neurological functions and may have potential benefits in these areas. However, it is important to note that the patent does not provide any specific details about the mechanism of action or clinical evidence supporting the effectiveness of the method.
Further research and clinical trials would be necessary to validate the claims made in this patent and determine the actual efficacy and safety of the proposed method. If proven successful, this method could potentially lead to the development of new pharmaceutical products or functional foods targeting cognitive function, anxiety, and cerebral atrophy.
To know more about GlobalData’s detailed insights on Ajinomoto, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
